StemCell Therapy

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota.

Irish based life sciences company Malin said on Monday that it has acquired a 32 per cent shareholding of US biotechnology company Artizan Biosciences.

Dublin-based Malin, which has invested more than 300 million in life sciences companies since it was established in early 2015, invested in Artizan via a founding equity round alongside Hatteras Venture Partners, a venture capital firm with which Malin has a strategic partnership.

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota. It was spun out of Yale University and established as a standalone business in 2016 and its founders include Prof. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD, from Yale University. Artizan, which aims to be a leader in the microbiota-driven inflammatory diseases space, has developed a capability of distinguishing certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for any number of digestive disorders as well as other diseases including obesity, autoimmune disease and a wide variety of skin, lung and central nervous system (CNS) diseases.

Artizans proposed approach is disruptive to current treatment and would offer new and novel therapeutic options for patients suffering from a broad array of inflammatory disorders, Adrian Howd, chief investment officer of Malin, said.

Last month Malin acquired a 33 per cent shareholding of Wren Therapeutics, a newly created biopharmaceutical company based in Cambridge, UK. It was set up by a number of former Elan executives in 2015.

Read more from the original source:
Malin stakes 32% take in US biotechnology company Artizan - Irish Times

Commentary | Feb. 3, 2017

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil

Should Christians face unethical uses of biotechnology with despair and resignation or with hope and determination?

Ive spent the last decade writing and speaking about the remarkable and terrifying world of biotechnology from a Catholic perspective. Many times Ive felt like Frodo Baggins at the gates of Mordor, looking upon Mt. Doom with despair and dread.

Ive never felt this more acutely than in the past few months. A series of recent headlines have renewed my sense of hopelessness in the face of the never-ending assault on the dignity of human life by modern biotechnology.

The gloom began to settle when it was revealed that a Swedish scientist is editing the DNA of healthy human embryos.Fredrik Lanner,a developmental biologist, is using a new gene-editing technique called CRISPR to disable some genes in healthy human embryos to see how those genes affect development. He and his team are intentionally modifyingotherwise healthy IVFembryos so they cannot develop properly.

Anin-depth story byNPRreveals that while the reporter was observing thegeneticmanipulation of five donated IVF embryos, one didnt survive the thawing process and one perished after being injected with the experimental gene-editing tool. Of the three who survived, one continued to divide, but not for long.All of the embryos were to be destroyedbefore they are 15 days old,as the law in Sweden dictates. Lanner insists that his research is critical to understanding human development, which, in turn, will shed light on infertility and disease.

Lanners work makes many ethicists and scientists extremely nervous. Jennifer Doudna, the co-inventor of CRISPR, along with other heavy-hitting scientists,havecalled for a voluntary moratorium on any editing of human embryosfor fear that it will lead to the creation of genetically modified children. Marcy Darnovsky, of the left-leaning Center for Genetics and Society, explains why she and her group havebeen so vocal in their opposition to the modification of human embryos. She told NPR: The production of genetically modified human embryos is actually quite dangerous. ... When youre editing the genes of human embryos, that means youre changing the genes of every cell in the bodies of every offspring, every future generation of that human being. So these are permanent and probably irreversible changes that we just dont know what they would mean.

Then came the revelation that a U.S. doctor traveled to Mexico to create the first baby intentionally engineered to have three genetic parents. This technique, misnamed mitochondrial replacement or MR, seeks to eliminate the transmission of genetic disease through the mitochondria.Mitochondria are small but abundant organellesoutside the nucleusinthe cytoplasmof our cells that make energy. They have their own DNA called mtDNA. We inherit our mtDNA solely from our mothers. A woman who carries a deleterious mutation in her mtDNA cannot help but pass that on to her offspring.

There are various MR techniques that replace the mitochondria of a woman with mitochondrial disease with the mitochondria of a donor femalein the IVF process.Essentially, MR creates a genetically alteredembryo with the genetic material from three people, one man and two women.

MR had only undergone limited study in primates before getting approval in the United Kingdom for use in fertility clinics to make babies. Little is known about the complexcommunication between the DNA in the nucleus and the DNA in the mitochondria,and so there is little data on the effects ofa mismatch between the nuclear DNA and mtDNA.

Alsoin all MR, its the nucleus thats being moved from cell to cell, not the mitochondria which is why mitochondrial replacement is such a misnomer.This makes MR acousin to cloning, which also transplants the nucleus of one cell into anotherto make a new organism. MR brings with it many of the same risks.Scientists are concerned about the health of the resulting children.

In anopen letterto the U.K. Parliament, Dr. Paul Knoepfler, a vocal American stem-cell researcher, warned: Even if, hypothetically, this technology might help avoid some people from having mitochondrial disorders (and thats a big if), the bottom line is that there is an equal or arguably greater chance that it will tragically produce very ill or deceased babies.

MRis also a germ-line genetic modification, which means that any girl born with this technique will pass her genetic modification on to her children.

A recent review in Nature reveals that MR leaves a tiny percentage of mutant mitochondria behind, and sometimes the mutant mitochondria rapidly divide and overtake the healthy mitochondria. Shoukhrat Mitalipov, head of the Center for Embryonic Cell and Gene Therapy at the Oregon Health and Science University, reported a 15% failure rate where mitochondrial defects returned. Mitalipov told NPR, That original, maternal mitochondrial DNA took over, and it was pretty drastic. There was less than 1% of the original maternal mitochondrial DNA present after replacement with donor DNA and before fertilization, and yet it took over the whole cell later. University of California San Francisco professor Patrick OFarrell suggests that mutant mitochondria can resurge at any time in a developing three-parent child or even resurface in future generations.

For all these reasons, MR is not yet approved by the FDA in the United States,and may never be.So, when a Jordanian woman with mitochondrial disease wanted to have a child using MR, John Zhang, from the New Hope Fertility Center in New York City, had to perform the procedure in Mexico. He created five embryos,and, according toNewScientist.com,only one developed normally. That child is now 9 months old.

Zhang went to Mexico because, he said, there are no rules, and yet he insists he did the safe and ethical thingin the absence of any medical or ethical oversight. In an ironic twist, the couple is Muslim and so chose the MR technique that wouldnt destroy existing embryos.But it was clear that only male embryos would be transferred for gestation, because boys cant pass on the genetic modification. What happened to the other four embryos, however? Were they destroyed,discarded or frozen? If they were females, would they have been destroyed anyway to make sure they couldnt pass on any ill effects?

Darnovskycalledthis rogue experimentationand added, No researcher or doctor has the right to flout agreed-upon rules and make up their own. This is an irresponsible and unethical act.

Knoepflerrespondedto the news by remindingus that this is a living human experiment that is going to unfold over years and decades. It is also worth noting that this child is a genetically modified human being as a result of this technique.

Of course, these are happenings to despair of not only because of the sheer disregard for the sanctity of individual human lives, but because of the breakneck speed at which scientists are kicking ethical lines farther and farther down the road like a tin can. All the while, they insist that its for the good of humanity. I wonder: How can wetreatindividual members of the human species so callously and then, at the same time, say its for the good of the whole human race?

I fear there is no line we wont cross;no ethical boundary wewonttear down in the name of science.

On a daily basis, Im surrounded by science and scientists. Often, their response to this madness is that its going to happen anyway, and theres no way to stop it, which implies we must go along to get along all in the name of progress.

If I am Frodo, then they and the rest of society are Saruman giving in to the despair and making a deal with Sauron.In the film version of The Lord of the Rings, Saruman says to Gandalf: Against the power of Mordor there can be no victory. We must join with him, Gandalf. We must join with Sauron. It would be wise, my friend.

Gandalf replies, Tell me, friend, when did Saruman the Wise abandon reason for madness?

Indeed. When did science abandon reason for madness, ethics for recklessness?

So what shall we do? If wesuccumb to despair, we become like Saruman.

We always have prayer. Its time toadd human embryonic research and germ-line human genetic engineering to our list of life issues that we pray about.It doesnt matter whether we understand the finer points of the science or not.Praying for an end to abortion andassisted suicide is nolongerenough.

In addition to prayer, there are other things we can do. The first is to vote pro-life at every level of government, from city council to state assemblymen. Being pro-life isnt just about abortion, however. Its about protecting the sanctity of life from the beginning to the end. Pro-life legislators, even if they cannot overturn Roe v. Wade, can effect local and state laws and steer funding away from unethical research.

Secondly, we must fight for conscience rights for medical professionals. I envision a not-so-far-off world wheredoctorsare forced into making genetically engineered embryos and bringing these children to term simply because parents claim its their reproductive right to have the children of their design. Without conscience rights, unethical experimentation on the next generation will be rampant and unchecked.

We must, however, always have hope. Whenstaring downthe juggernaut that is modern biotechnology, I always remember Frodo Baggins.When he was faced with the seemingly impossible task of taking the One Ring to Mordor, instead of shying away because it was too hard, he said: I will take the Ring, though I do not know the way.

Rebecca Tayloris a

clinical laboratory specialist in molecular biology.

She writes about bioethics on her blog,Mary Meets Dolly.

Excerpt from:
Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil - National Catholic Register

President Trump pressed Big Pharma executives to increase U.S. production and lower drug prices.

As biotechnology stocks have been showing momentum following a meeting between President Trump and pharmaceutical executives Tuesday, our two long investments to watch are in that sector. There are also several shorts among our charts to watch to play the potential downside in this near-term, toppy-looking stock market.

Gene-therapy company bluebird bio Inc. BLUE, -2.10% has a strong-looking chart. The stock recently broke out of a wedge pattern, in which its price range had narrowed for two months in essentially a sideways direction. The stock continued the upmove on Tuesday when it popped $5.90, or over 8%, to $74.50, and followed through for another $1.10 on Wednesday to $75.60. The stock is now positioned to challenge its recent high at $79.70 from early December. A break through there could lead to a move into the mid-$80s, followed by a next target in the mid-$90s. With short interest of 9.2 its average volume, the price advance could be further fueled by short covering.

Cara Therapeutics Inc. CARA, -0.90% a cannabis-based biotech, has been steadily climbing since the start of the year. On Wednesday, the stock popped $1.17, or 7.6%, to $16.49 on 4.7 million shares, which is huge volume for this stock, the biggest since mid-November. The stock got as high as $17.20 intraday before pulling back into the close. It is a bit extended near the top of its channel and could pull back and consolidate before its next move, but momentum could carry it a bit further toward $18.

On the short side, Carters Inc. CRI, +0.26% continues lower since its July 2016 top above $112. On Wednesday, shares in the childrens wear retailer were down another $1.05, or 1.3%, to $82.70, on 690,100 shares traded. The stock appears headed toward the bottom of its declining channel in the $73-$74 range.

Signet Jewelers Ltd. SIG, -0.67% is also continuing lower. The stock rallied from the bottom of its declining price channel to the top in the last quarter of 2016, but has since broken down. Shares fell another 66 cents to $77.01 on 1.5 million shares traded on Wednesday. Watch for a test of the late-September low in the $72-$73 range. A takeout of that could drop the stock near its channel bottom in the low- to mid-$60s.

See Harrys video chart analysis on these and other stocks.

The writer has no holdings in any securities mention in this article.

Harry Boxer is the founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

Follow this link:
Opinion: Harry Boxer: Watch these two biotechnology stocks - MarketWatch

More Volatility Ahead for Biotechnology Sector Wall Street Journal (blog) After underperforming the S&P 500 over the past six months, the biotechnology sector is poised for more volatility ahead. The group drew plenty of attention on the campaign trail as both and Democratic candidate criticized the high prices for drugs ...

Link:
More Volatility Ahead for Biotechnology Sector - Wall Street Journal (blog)

Intrexon Corporation (XON) ended last trading session with a change of 5.25 percent. It trades at an average volume of 1.33M shares versus 1.7M shares recorded at the end of last trading session. The share price of $22.04 is at a distance of 8.09 percent from its 52-week low and down -45.23 percent versus its peak. The company has a market cap of $2.61B and currently has 118.35M shares outstanding. The share price is currently -5.82 percent versus its SMA20, -16.17 percent versus its SMA50, and -17.92 percent versus its SMA200. The stock has a weekly performance of 2.04 percent and is -9.3 percent year-to-date as of the recent close.

Jan. 26, 2017 Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (XON) committed to enabling the study of life-threatening human diseases, has been awarded a subcontract to create genetically engineered miniswine models of sickle cell disease as part of a national resource that could lead to new treatments for the disorder.

The subcontract is with Leidos Biomedical Research, Inc., prime contractor for the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, part of the National Institutes of Health (NIH). Work under the subcontract will support the NIHs National Center for Advancing Translational Sciences (NCATS) in creating genetically engineered miniswine models of sickle cell disease. Exemplar Genetics will develop several versions of genetically engineered miniswine models of sickle cell disease that more accurately replicate the human pathology as compared to traditional research models.

Keryx Biopharmaceuticals, Inc. (KERX) recently recorded -0.55 percent change and currently at $5.45 is 75.24 percent away from its 52-week low and down -30.13 percent versus its peak. It has a past 5-day performance of 13.54 percent and trades at an average volume of 1.61M shares. The stock has a 1-month performance of -12.38 percent and is -7 percent year-to-date as of the recent close. There were about 106.55M shares outstanding which made its market cap $580.7M. The share price is currently -1.7 percent versus its SMA20, -5.27 percent versus its SMA50, and -1.49 percent versus its SMA200.

Nov. 18, 2016 Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced case study data, which showed that Auryxia (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation at the American Society of Nephrologys 2016 Kidney Week taking place in Chicago.

The rest is here:
Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) - The Independent Republic

Achillion Pharmaceuticals, Inc. (ACHN) ended last trading session with a change of 2.61 percent. It trades at an average volume of 2.22M shares versus 1.78M shares recorded at the end of last trading session. The share price of $4.32 is at a distance of 14.29 percent from its 52-week low and down -57.06 percent versus its peak. The company has a market cap of $575.38M and currently has 133.19M shares outstanding. The share price is currently 2.99 percent versus its SMA20, 3.06 percent versus its SMA50, and -38.89 percent versus its SMA200. The stock has a weekly performance of 5.62 percent and is 4.6 percent year-to-date as of the recent close.

On Dec. 28, 2016 Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment in the OMEGA-1 Phase 2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335 in patients with treatment-naive chronic hepatitis C virus infection (HCV) without cirrhosis.

We are delighted to have reached this milestone following Janssens recent initiation of the OMEGA-1 global clinical trial evaluating JNJ-4178, a once-daily combination of AL-335, simeprevir, and the Achillion-discovered NS5A inhibitor, odalasvir, and we look forward to JNJ-4178s continued clinical advancement, commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion.

Stemline Therapeutics, Inc. (STML) recently recorded 16.96 percent change and currently at $6.55 is 68.81 percent away from its 52-week low and down -55.14 percent versus its peak. It has a past 5-day performance of -35.78 percent and trades at an average volume of 285.02K shares. The stock has a 1-month performance of -44.96 percent and is -38.79 percent year-to-date as of the recent close. There were about 20.21M shares outstanding which made its market cap $132.38M. The share price is currently -41.5 percent versus its SMA20, -44.82 percent versus its SMA50, and -29.73 percent versus its SMA200.

Feb. 02, 2017 Stemline Therapeutics, Inc. (STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, provides an update on its ongoing pivotal Phase 2 trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN), using Stemlines experimental compound, SL-401. BPDCN at present has no approved treatment.

On January 18, the Company received a report that a patient death had occurred. The patient had developed capillary leak syndrome (CLS), a known, sometimes fatal, and well-documented side effect of SL-401. The cause of the patients death has not yet been determined. The safety profile for SL-401 includes CLS, and there have been previous deaths reported in patients with CLS in this trial, which have been disclosed in public presentations. That CLS is an expected complication of the administration of SL-401 has also been identified in filings with the Securities and Exchange Commission (SEC) and U.S. Food and Drug Administration (FDA), as well as in the studys informed consent forms and other information provided to investigators.

See the article here:
2 Sizzling Hot Biotechnology Stocks: Achillion Pharmaceuticals, Inc. (ACHN), Stemline Therapeutics, Inc. (STML) - The Independent Republic

Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of 2.08 percent. It trades at an average volume of 2.28M shares versus 1.33M shares recorded at the end of last trading session. The share price of $3.43 is at a distance of 20.35 percent from its 52-week low and down -60.8 percent versus its peak. The company has a market cap of $340.19M and currently has 99.18M shares outstanding. The share price is currently -2.15 percent versus its SMA20, -7.49 percent versus its SMA50, and -13.68 percent versus its SMA200. The stock has a weekly performance of 1.48 percent and is -3.11 percent year-to-date as of the recent close.

On Dec. 14, 2016 Celldex Therapeutics, Inc. (CLDX) announced the appointment of Gerald McMahon, Ph.D., to the Companys Board of Directors. Dr. McMahon was previously the President and Chief Executive Officer of Kolltan Pharmaceuticals. In addition, the Company announced that Richard van den Broek has resigned from the Board due to increasing responsibilities in other endeavors.

Dr. McMahon brings an exceptional background in science and drug development, particularly in the oncology space, to the Celldex Board, said Larry Ellberger, Chairman of the Board of Directors at Celldex Therapeutics. We believe he will be a valuable addition as we advance a robust pipeline, which now also includes drug candidates targeting receptor tyrosine kinases, an area of expertise for Jerry. I would also like to recognize Rich for his contributions to Celldex. We wish him all the best in his future endeavors.

Eleven Biotherapeutics, Inc. (EBIO) recently recorded 4.61 percent change and currently at $2.27 is 804.38 percent away from its 52-week low and down -61.98 percent versus its peak. It has a past 5-day performance of 4.13 percent and trades at an average volume of 1.15M shares. The stock has a 1-month performance of -1.73 percent and is 18.85 percent year-to-date as of the recent close. There were about 23.17M shares outstanding which made its market cap $52.6M. The share price is currently 5.56 percent versus its SMA20, 4.83 percent versus its SMA50, and -9.19 percent versus its SMA200.

On November 14, 2016 Eleven Biotherapeutics, Inc. (EBIO) reported financial results for the third quarter ended September 30, 2016, and recent business highlights.

This is an exciting period for Eleven. We completed the Roche licensing deal, including $30 million in upfront and milestone payments received to date. We also completed the acquisition of Viventia Bio Inc. which allowed us to become a late-stage oncology company. Perhaps most excitingly, we are making significant progress in moving forward what we believe could be therapeutics that materially improve patients lives. We anticipate complete enrollment in the first half of next year for our Phase 3 clinical trial of Vicinium as a potential treatment for high-grade non-muscle invasive bladder cancer, and expect topline data in the first half of 2018, said Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics. We also plan to initiate our Phase 2 trial in late-stage squamous cell carcinoma of the head and neck with Proxinium in combination with a checkpoint inhibitor in the first half of 2017. Also in 2017, we plan on submitting an IND with the FDA for our lead product in our systemic pipeline based on our proprietary payload deBouganin. With the combined expertise of Eleven and the Viventia team, I am very excited about the opportunities we have ahead.

Go here to read the rest:
Two Biotechnology Names Are Hot: Celldex Therapeutics, Inc. (CLDX), Eleven Biotherapeutics, Inc. (EBIO) - The Independent Republic

Considering a Masters in Biotechnology Program or reviewing options for Masters Degrees in Biotechnology? A Masters in Biotechnology can openupexciting

Biotechnology is a challenging field that can involve a number of facets of both science and business or law. Many biotechnology master's degree programs focus on aspects of biology, cell biology, chemistry, or biological or chemical engineering. In general, biotechnology degrees involve research whether they are at a Masters or PhD level.

Scientific understanding is rapidly evolving, particularly in areas of cellular and molecular systems. Biotechnology master's students can therefore enjoy rich study opportunities particularly in fields such as genetic engineering, the Human Genome project, the production of new medicinal products, and research into the relationship between genetic malfunction and the origin of disease. These are just a few of the many areas that biotechnology students have the opportunity to explore today.

Another focus of biotechnology masters programs may be to equip students with the combination of science and business knowledge they need to help produce products and move them toward production. Today's complex business environment and government regulations require many steps and people with the ability to both understand and help produce new scientific technologies as well as get them approved and be able to market them.

Master degrees in biotechnology might prepare students to pursue careers in a variety of industries. While many students go on to further research or academic positions, there may also be some demand for biotechnologists outside of academia, both in the government and private sectors. Biotechnologists might pursue careers in anything from research to applied science and manufacturing. Those with specializations in business aspects of biotechnology may be qualified to pursue management positions within organizations attempting to produce and market new biotechnology.

More:
Masters in Biotechnology Programs and Degrees in Biotechnology

Biotechnology has proven to be an important tool for better sustainability and food security. It helps farmers grow more food while improving the environment. For example, biotechnology reduces the use of costly inputs and improves weed management, allowing farmers to reduce tillage for better soil, water and air quality. Today, roughly 90 percent of corn, cotton and soybeans grown in the U.S. have been improved through biotechnology, and farmers are choosing biotech traits when growing other crops such as alfalfa, sugarbeets and canola.

Despite rapid adoption by farmers and a strong scientific consensus that biotechnology does not pose health and environmental risks, regulatory burdens are slowing research and innovation of new biotech traits and are starting to reduce U.S. farmers international competitive advantage. In addition, activist groups routinely threaten the availability of new traits by blocking science-based regulatory decisions, filing lawsuits and advocating for labeling mandates.

GM crops require less water and fewer chemical applications than conventional crops, and they are better able to survive drought, weeds, and insects.

U.S. agriculture will maintain its competitive advantage in world markets only if we continue to support innovations in technology and grasp opportunities for future biotech products.

To improve regulation of biotechnology, Farm Bureau supports:

Farm Bureau encourages efforts to educate farmers to be good stewards of biotech crops to preserve accessand marketability.

Farm Bureau believes agricultural products grown using approved biotechnology should not be subject to mandatory labeling. We supportexisting FDA labeling policies and opposestate policies on biotech labeling, identification, use and availability.

On July 29, 2016 the president signed S. 764, the National Bioengineered Food Disclosure Standard, into law. While not perfect, S. 764 was a compromise that Farm Bureau endorsed. The law creates a uniform standard for the disclosure of ingredients derived from bioengineering and allows food companies to provide that information through an on-package statement, symbol or electronic disclosure. It also created a strong federal preemption provision to protect interstate commerce and prevent state-by-state labeling laws and was effective on the date of enactment. USDA has two years to develop the disclosure standards and Farm Bureau will be an active participant in the rulemaking process.

Farm Bureau supports active involvement and leadership by the U.S. government in the development of international standards for biotechnology, including harmonization of regulatory standards, testing and LLP policies.

This resource can help set the record straight on GMOs, to correct misinformation and show why biotechnology is so important to agriculture.

Benefits of Biotech Toolkit (PDF)

Here is the original post:
Biotechnology - fb.org

3 Biotech is a quarterly, peer-reviewed open access journal published under the brand SpringerOpen.

Continuous Article Publishing (CAP)

3 Biotech will be moving to the Continuous Article Publishing (CAP) in 2016, in which newly accepted papers will be published online with volume and article numbers, shortly after receipt of authors proofs. This change will alleviate the significant backlog of accepted articles that are currently available online as "published ahead of time," but are awaiting formal publication with a volume, issue number and page numbers. To achieve a smooth transition to the CAP model, all papers that have been accepted after June 2015 have been held back and will be published with volume and article numbers from January 2016 onwards. We wish to apologize for this short delay in article processing during this important transition phase, which is designed to speed up the process from acceptance of articles to final publication without the need for articles to be placed in a "published ahead of time" waiting line. In addition, a formal rapid publication from 2016 will ensure that all articles in 3 Biotech are immediately available in indexing services for researchers.

3 Biotech publishes the results of the latest research related to the study and application of biotechnology to:

- Medicine and Biomedical Sciences - Agriculture - The Environment

The focus on these three technology sectors recognizes that complete Biotechnology applications often require a combination of techniques. 3 Biotech not only presents the latest developments in biotechnology but also addresses the problems and benefits of integrating a variety of techniques for a particular application. 3 Biotech will appeal to scientists and engineers in both academia and industry focused on the safe and efficient application of Biotechnology to Medicine, Agriculture and the Environment.

Articles from a huge variety of biotechnology applications are welcome including:

- Cancer and stem cell research - Genetic engineering and cloning - Bioremediation and biodegradation - Bioinformatics and system biology - Biomarkers and biosensors - Biodiversity and biodiscovery - Biorobotics and biotoxins - Analytical biotechnology and the human genome

3 Biotech accepts original and review articles as well as short research reports, protocols and methods, notes to the editor, letters to the editor and book reviews for publication. Up to date topical review articles will also be considered. All the manuscripts are peer-reviewed for scientific quality and acceptance.

NEW:

3Biotech hasrecently receivedits first Impact Factor and is nowcovered by a range of A&I services, including:

- Science Citation Index Expanded - Journal Citation Reports/Science Edition - Biological Abstracts - BIOSIS Previews

Best Paper Award: 3 Biotech is supported by King Abdulaziz City for Science and Technology (KACST) in Saudi Arabia. Every year KACST awards the best paper with the KACST Medal and $5,000. The editors of 3 Biotech have elected the best paper among those published in 2011-2012 and 2012-2013.

- The 2011-2012 winning paper is:

Nanocrystalline hydroxyapatite and zinc-doped hydroxyapatite as carrier material for controlled delivery of ciprofloxacin

Authors: G. Devanand Venkatasubbu and colleagues at Anna University, India.

- The 2012-2013winning paper is: Stress influenced increase in phenolic content and radical scavenging capacity of Rhodotorula glutinis CCY 20-2-26 Authors: Raj Kumar Salar and colleagues at Chaudhary Devi Lal University, India.

Related subjects Agriculture - Biomaterials - Biotechnology - Cancer Research - Cell Biology - Systems Biology and Bioinformatics

Journal Citation Reports, Thomson Reuters

Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed, PubMedCentral, EMBASE, Google Scholar, CAB International, AGRICOLA, Biological Abstracts, BIOSIS, CAB Abstracts, DOAJ, Global Health, OCLC, Summon by ProQuest

See original here:
3 Biotech - a SpringerOpen journal

Session & Tracks

Track 1:Molecular Biotechnology

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment.Molecular biotechnologyresults from the convergence of many areas of research, such as molecular biology, microbiology,biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product.

Related Conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th-14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA;BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil;Bio Pharm America 20158th Annual International Partnering Conference, September 15-17, 2015, Boston, MA, USA.

Track 2:Environmental Biotechnology

The biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. It is "the development, use and regulation of biological systems for remediation of contaminated environment and forenvironment-friendly processes(green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to producerenewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".

Related Conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands

Track 3:Animal Biotechnology

It improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment. Animalbiotechnologyis the use of science and engineering to modify living organisms. The goal is to make products, to improve animals and to developmicroorganismsfor specific agricultural uses. It enhances the ability to detect, treat and prevent diseases, include creating transgenic animals (animals with one or more genes introduced by human intervention), using gene knock out technology to make animals with a specific inactivated gene and producing nearly identical animals by somatic cell nuclear transfer (or cloning).

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 4:Medical Biotechnology and Biomedical Engineering

Medicine is by means of biotechnology techniques so much in diagnosing and treating dissimilar diseases. It also gives opportunity for the population to defend themselves from hazardous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technologyand polymerase chain retort which employ genes and DNA molecules to make adiagnosis diseasesand put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & Biotech Patent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 5:Agricultural Biotechnology

Biotechnology is being used to address problems in all areas of agricultural production and processing. This includesplant breedingto raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques asMarker Assisted Breeding, which increases the effectiveness of conventional breeding.

Related Conferences

3rd GlobalFood Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;Biologically Active Compoundsin Food, October 15-16 2015 Lodz, Poland; World Conference onInnovative Animal Nutrition and Feeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood Science and Biotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference on Agricultural Science, Biotechnology,Food and Animal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia.

Track 6:Industrial Biotechnology and Pharmaceutical Biotechnology

Industrial biotechnology is the application of biotechnology for industrial purposes, includingindustrial fermentation. The practice of using cells such as micro-organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles andbiofuels. Industrial Biotechnology offers a premier forum bridging basic research and R&D with later-stage commercialization for sustainable bio based industrial and environmental applications.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 8:Microbial and Biochemical Technology

Microorganisms have been exploited for their specific biochemical and physiological properties from the earliest times for baking, brewing, and food preservation and more recently for producingantibiotics, solvents, amino acids, feed supplements, and chemical feedstuffs. Over time, there has been continuous selection by scientists of special strains ofmicroorganisms, based on their efficiency to perform a desired function. Progress, however, has been slow, often difficult to explain, and hard to repeat. Recent developments inmolecular biologyand genetic engineering could provide novel solutions to long-standing problems. Over the past decade, scientists have developed the techniques to move a gene from one organism to another, based on discoveries of how cells store, duplicate, and transfer genetic information.

Related conferences

3rdGlobal Food Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;Biologically Active Compoundsin Food, October 15-16 2015 Lodz, Poland; World Conference onInnovative Animal Nutrition and Feeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood Science and Biotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference on Agricultural Science, Biotechnology,Food and Animal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia.

Track 9:Food Processing and Technology

Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life. Biotechnology helps in improving the edibility, texture, and storage of the food; in preventing the attack of the food, mainly dairy, by the virus likebacteriophage producing antimicrobial effect to destroy the unwanted microorganisms in food that cause toxicity to prevent the formation and degradation of other toxins andanti-nutritionalelements present naturally in food.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress 2016, May 11th-14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA;BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil;Bio Pharm America 20158th Annual International Partnering Conference, September 15-17, 2015, Boston, MA, USA.

Track 10:Genetic Engineering and Molecular Biology

One kind of biotechnology is gene technology, sometimes called 'genetic engineering' or'genetic modification', where the genetic material of living things is deliberately altered to enhance or remove a particular trait and allow the organism to perform new functions. Genes within a species can be modified, or genes can be moved from one species to another. Genetic engineering has applications inmedicine, research, agriculture and can be used on a wide range of plants, animals and microorganisms. It resulted in a series of medical products. The first two commercially prepared products from recombinant DNA technology were insulin andhuman growth hormone, both of which were cultured in the E. coli bacteria.

The field of molecular biology overlaps with biology and chemistry and in particular, genetics and biochemistry. A key area of molecular biology concerns understanding how various cellular systems interact in terms of the way DNA, RNA and protein synthesis function.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-http://world.biotechnologycongress.com/08, 2015 Berlin, Germany, DEU.

Track 11:Tissue Science and Engineering

Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, orsemisynthetic tissueand organ mimics that are fully functional from the start or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results includetissue-engineeredbone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 12:Nano Biotechnology

Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found inNano biologyinvolve applying Nano tools to relevantmedical/biologicalproblems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.

Related Conferences

8thWorldMedicalNanotechnologyCongress& Expo during June 9-11, Dallas, USA; 6thGlobal Experts Meeting and Expo onNanomaterialsand Nanotechnology, April 21-23, 2016 ,Dubai, UAE; 12thNanotechnologyProductsExpo, Nov 10-12, 2016 at Melbourne, Australia; 5thInternationalConference onNanotechand Expo, November 16-18, 2015 at San Antonio, USA; 11thInternational Conference and Expo onNano scienceandMolecular Nanotechnology, September 26-28 2016, London, UK; 18thInternational Conference onNanotechnologyand Biotechnology, February 4 - 5, 2016 in Melbourne, Australia; 16thInternational Conference onNanotechnology, August 22-25, 2016 in Sendai, Japan; International Conference onNano scienceand Nanotechnology, 7-11 Feb 2016 in Canberra, Australia; 18thInternational Conference onNano scienceand Nanotechnology, February 15 - 16, 2016 in Istanbul, Turkey; InternationalNanotechnologyConference& Expo, April 4-6, 2016 in Baltimore, USA.

Track 13:Bioinformatics and Biosensors

Bioinformatics is the application of computer technology to the management of biological information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied to gene-based drug discovery and development. The science of Bioinformatics, which is the melding of molecular biology with computer science, is essential to the use of genomic information in understanding human diseases and in the identification of newmolecular targetsfor drug discovery. This interesting field of science has many applications and research areas where it can be applied. It plays an essential role in today's plant science. As the amount of data grows exponentially, there is a parallel growth in the demand for tools and methods indata management, visualization, integration, analysis, modeling, and prediction.

Related conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBio based Chemicals: Commercialization & Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnology and Bio economy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnology World Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess Engineering and Technology, 20th to 22nd January 2016,Kolkata, India; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA

Track 14:Biotechnology investments and Biotech grants

Every new business needs some startup capital, for research, product development and production, permits and licensing and other overhead costs, in addition to what is needed to pay your staff, if you have any. Biotechnology products arise from successfulbiotechcompanies. These companies are built by talented individuals in possession of a scientific breakthrough that is translated into a product or service idea, which is ultimately brought into commercialization. At the heart of this effort is the biotech entrepreneur, who forms the company with a vision they believe will benefit the lives and health of countless individuals. Entrepreneurs start biotechnology companies for various reasons, but creatingrevolutionary productsand tools that impact the lives of potentially millions of people is one of the fundamental reasons why all entrepreneurs start biotechnology companies.

10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok; 11thEuroBiotechnologyCongress, November 7-9, 2016 Alicante, Spain; 11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 13thBiotechnologyCongress, November 28-30, 2016 San Francisco, USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, UAE;BioInternational Convention, June 6-9, 2016 | San Francisco, CA;BiotechJapan, May 11-13, 2016, Tokyo, Japan;NANO BIOEXPO 2016, Jan. 27 - 29, 2016, Tokyo, Japan;ArabLabExpo2016, March 20-23, Dubai; 14thInternational exhibition for laboratory technology,chemical analysis, biotechnology and diagnostics, 12-14 Apr 2016, Moscow, Russia

Read this article:
Biotechnology Conferences | USA Biotech events ...

Journal of Biotechnology & Biomaterials is a peer reviewed journal which publishes high quality articles reporting original research, review, commentary, opinion, rapid communication, case report etc. on all aspects of Biotechnology and Biomaterials. Content areas include Plant/Animal/Microbial Biotechnology, Applied Biotechnology, Red/Medical Biotechnology, Green/Agricultural Biotechnology, Environmental Biotechnology, Blue/Marine Biotechnology, White/Industrial Biotechnology, Food Biotechnology, Orthopedic and Dental Biomaterials, Cardiovascular Biomaterials, Ophthalmologic Biomaterials, Bioelectrodes and Biosensors, Burn Dressings and Skin Substitutes, Sutures, Drug Delivery Systems etc. This Biotechnology Journal with highest impact factor offers Open Access option to meet the needs of authors and maximize article visibility.

The journal is an academic journal providing an opportunity to researchers and scientists to explore the advanced and latest research developments in the use of living organisms and bioprocesses in engineering, technology and medicine. The Journal of Biotechnology and Biomaterials is of highest standards in terms of quality and provides a collaborative open access platform to the scientists throughout the world in the field of Biotechnology and Biomaterials. Journal of Biotechnology and Biomaterials is a scholarly Open Access journal and aims to publish the most complete and reliable source of information on the advanced and very latest research topics.

The journal is using the Editorial Manager System for quality in the peer-review process. Editorial Manager System is an online submission and review system, where authors can submit manuscripts and track their progress. Reviewers can download manuscripts and submit their opinions. Editors can manage the whole submission, review, revise & publish process. Publishers can see what manuscripts are in the pipeline awaiting publication.

The Journal assures a 21 days rapid review process with international peer-review standards and with quality reviewers. E-mail is sent automatically to concerned persons when significant events occur. After publishing, articles are freely available through online without any restrictions or any other subscriptions to researchers worldwide.

Applied Biotechnology is gives the major opportunity to study science on the edge of technology, innovation and even science itself. Applied Microbiology and Biotechnology focusses on prokaryotic or eukaryotic cells, relevant enzymes and proteins; applied genetics and molecular biotechnology; genomics and proteomics; applied microbial and cell physiology; environmental biotechnology; process and products and more.

Related Journals of Applied Biotechnology

Current Opinion in Biotechnology, Biotechnology Advances, Biotechnology for Biofuels, Journal of Bioprocessing & Biotechniques, Journal of Bioterrorism & Biodefense, Molecular Biology, Biology and Medicine, Crop Breeding and Applied Biotechnology, Applied Mycology and Biotechnology, Asian Biotechnology and Development Review, Biotechnology applications Journals, Journal of Applied Biomaterials & Fundamental Materials.

Biomaterials are commonly used in various medical devices and systems such as drug delivery systems, hybrid organs, tissue cultures, synthetic skin, synthetic blood vessels, artificial hearts, screws, plates, cardiac pacemakers, wires and pins for bone treatments, total artificial joint implants, skull reconstruction, and dental and maxillofacial applications. Among various applications, the application of biomaterials in cardiovascular system is most significant. The use of cardiovascular biomaterials (CB) is subjected to its blood compatibility and its integration with the surrounding environment where it is implanted.

Related Journals of Cardiovascular biomaterials

Journal of Biomimetics Biomaterials and Tissue Engineering, Journal of Advanced Chemical Engineering, Journal of Bioprocessing & Biotechniques, Journal of Biomaterials Science, Polymer Edition, Journal of Biomaterials Applications, Trends in Biomaterials and Artificial Organs, International Journal of Biomaterials and Journal of Biomaterials and Tissue Engineering, Cardiovascular biomaterials Journals.

Biomaterials are used daily in surgery, dental applications and drug delivery. Biomaterial implant is a construct with impregnated pharmaceutical products which can be placed into the body, that permits the prolonged release of a drug over an extended period of time. A biomaterial may also be an autograft, allograft or xenograft used as a transplant material.

Related journals of Biomaterial implants

Advanced Functional Materials, Biomaterials, Advanced healthcare materials, Journal of Biomimetics Biomaterials and Tissue Engineering, Journal of Molecular and Genetic Medicine, Journal of Phylogenetics & Evolutionary Biology, Clinical Oral Implants Research, International Journal of Oral and Maxillofacial Implants, Journal of Long-Term Effects of Medical Implants and Cochlear Implants International, Biomaterials Journals, Biomaterial implants Journals.

Animal Biotechnology covers the identification and manipulation of genes and their products, stressing applications in domesticated animals. Animals are used in many ways in biotechnology. Biotechnology provides new tools for improving human health and animal health and welfare and increasing livestock productivity. Biotechnology improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment.

Related Journals of Animal biotechnology

Journal of Bioprocessing & Biotechniques, Journal of Molecular and Genetic Medicine, Biology and Medicine, Journal of Advanced Chemical Engineering, Animal Biotechnology, African Journal of Biotechnology, Current Pharmaceutical Biotechnology, Critical Reviews in Biotechnology and Reviews in Environmental Science and Biotechnology, Asian Journal of Microbiology Biotechnology and Environmental Sciences.

A biomaterial is any surface, matter, or construct that interacts with biological systems. The biomaterial science is the study of biomaterials. Biomaterials science encloses elements of medicine, biology, chemistry, tissue engineering and materials science. Biomaterials derived from either nature or synthesized in the laboratory using a different typrs of chemicals utilizing metallic components, polymers, ceramics or composite materials. They are oftenly used for a medical application.

Related Journals of Biomaterials

Biosensors and Bioelectronics, Journal of Bioactive and Compatible Polymers, Journal of Tissue Engineering, Journal of Biomimetics Biomaterials and Tissue Engineering, Journal of Bioterrorism & Biodefense, Fermentation Technology, Journal of Phylogenetics & Evolutionary Biology, International Journal of Nano and Biomaterials, Journal of Biomimetics, Biomaterials, and Tissue Engineering, Journal of Applied Biomaterials and Fundamental Materials, Journal of Biomaterials and Tissue Engineering and International Journal of Biomaterials.

Nanobiotechnology, nanobiology and bionanotechnology are terms that refer to the intersection of nanotechnology and biology. Bionanotechnology and nanobiotechnology serve as blanket terms for various related technologies. This discipline helps to indicate the merger of biological research with various fields of nanotechnology. Concepts enhanced through nanobiology are nanodevices, nanoparticles, and nanoscale phenomena. Nanotechnology uses biological systems as the biological inspirations.

Related Journals of Nano biotechnology

Biopolymers, Journal of the Mechanical Behavior of Biomedical Materials, Journal of Tissue Engineering and Regenerative Medicine, Journal of Bioprocessing & Biotechniques, Journal of Bioterrorism & Biodefense, Journal of Molecular and Genetic Medicine, Journal of Advanced Chemical Engineering, Journal of Nanobiotechnology, Artificial Cells, Nanomedicine and Biotechnology, IET Nanobiotechnology and Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Australian journal of biotechnology, International Journal of Nano & Biomaterials, Nano biotechnology Journals.

Biocatalysis are used as natural catalysts, like protein enzymes, to perform chemical transformations on organic compounds. Both enzymes that have been more or less isolated and enzymes still residing inside living cells are employed for this task. Since biocatalysis deals with enzymes and microorganisms, it is historically classified separately from "homogeneous catalysis" and "heterogeneous catalysis". However, biocatalysis is simply a heterogeneous catalysis.

Related Journals of Biocatalysis

Biology and Medicine, Fermentation Technology, Journal of Advanced Chemical Engineering, Biocatalysis and Biotransformation and Biocatalysis and Agricultural Biotechnology.

Agricultural biotechnology is a collection of scientific techniques used to improve plants, animals and microorganisms. Based on an structure and characteristics of DNA, scientists have developed solutions to increase agricultural productivity. Scientists have learned how to move genes from one organism to another. This has been called genetic modification (GM), genetic engineering (GE) or genetic improvement (GI). Regardless of the name, the process allows the transfer of useful characteristics (such as resistance to a disease) into a plant, animal or microorganism by inserting genes from another organism.

Related Journals of Agricultural biotechnology

Journal of Phylogenetics & Evolutionary Biology, Journal of Molecular and Genetic Medicine, Molecular Biology, Journal of Bioprocessing & Biotechniques, Biocatalysis and Agricultural Biotechnology and Chinese Journal of Agricultural Biotechnology, Plant Biotechnology Journal, Plant Biotechnology Journals.

A biomolecule is any molecule which is present in living organisms, entails large macromolecules like proteins, lipids, polysaccharides, and nucleic acids, as well as small molecules include primary metabolites, secondary metabolites, and natural products. A common name for this class of material is biological materials. Nucleosides are molecules formed by attaching a nucleobase to a ribose or deoxyribose ring. Nucleosides can be phosphorylated by specific kinases in the cell, producing nucleotides.

Related Journals of Bio-molecules

Molecular Biology, Biology and Medicine, Journal of Molecular and Genetic Medicine, Journal of Phylogenetics & Evolutionary Biology, Biomolecules and Therapeutics, Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology, Asia-Pacific Journal of Molecular Biology and Biotechnology, Bio-molecules Journals.

In developing countries, application of biotechnology to food processing is an issue of argument and discussions for a long time. Biotechnological study focuse development and improvement of customary fermentation processes. The application of Biotechnology to solve the environmental problems in the environment and in the ecosystems is called Environmental Biotechnology. It is applied and used to study the natural environment.

Related Journals of Biotechnology applications

NatureBiotechnology, Trends inBiotechnology, MetabolicEngineering, Journal of Bioprocessing & Biotechniques,Journal of Phylogenetics & Evolutionary Biology, Journal ofAdvanced Chemical Engineering, Applied Microbiology andBiotechnology, Applied Biochemistry and Biotechnology - PartA Enzyme Engineering and Biotechnology, Biotechnology and AppliedBiochemistry, Applied Biotechnology Journals, Applied Microbiologyand Biotechnology, Systems and Synthetic Biology and IET SyntheticBiology.

Industrial or white biotechnology uses enzymes and micro-organisms to make biobased products in sectors like chemicals, food and feed, detergents, paper and pulp, textiles and bioenergy (such as biofuels or biogas). It uses renewable raw materials and is one of the most promising, newest approaches towards lowering greenhouse gas emissions. Industrial biotechnology application has been proven to make significant contributions towards mitigating the impacts of climate change in these and other sectors.

Related Journals of White/industrial biotechnology

Critical Reviews in Biotechnology, Biotechnology and Bioengineering, Microbial Biotechnology, Journal of Bioprocessing & Biotechniques, Journal of Bioterrorism & Biodefense, Fermentation Technology, Molecular Biology, Journal of Phylogenetics & Evolutionary Biology, Journal of Molecular and Genetic Medicine, Chemical Sciences Journal, Industrial Biotechnology and Journal of Industrial Microbiology and Biotechnology, White/industrial biotechnology Journals.

See original here:
Biotechnology Journals | Open Access - omicsonline.org

Considering a Masters in Biotechnology Program or reviewing options for Masters Degrees in Biotechnology? A Masters in Biotechnology can openupexciting

Biotechnology is a challenging field that can involve a number of facets of both science and business or law. Many biotechnology master's degree programs focus on aspects of biology, cell biology, chemistry, or biological or chemical engineering. In general, biotechnology degrees involve research whether they are at a Masters or PhD level.

Scientific understanding is rapidly evolving, particularly in areas of cellular and molecular systems. Biotechnology master's students can therefore enjoy rich study opportunities particularly in fields such as genetic engineering, the Human Genome project, the production of new medicinal products, and research into the relationship between genetic malfunction and the origin of disease. These are just a few of the many areas that biotechnology students have the opportunity to explore today.

Another focus of biotechnology masters programs may be to equip students with the combination of science and business knowledge they need to help produce products and move them toward production. Today's complex business environment and government regulations require many steps and people with the ability to both understand and help produce new scientific technologies as well as get them approved and be able to market them.

Master degrees in biotechnology might prepare students to pursue careers in a variety of industries. While many students go on to further research or academic positions, there may also be some demand for biotechnologists outside of academia, both in the government and private sectors. Biotechnologists might pursue careers in anything from research to applied science and manufacturing. Those with specializations in business aspects of biotechnology may be qualified to pursue management positions within organizations attempting to produce and market new biotechnology.

Excerpt from:
Masters in Biotechnology Programs and ... - Masters PhD Degrees

Environmental biotechnology is biotechnology that is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. The International Society for Environmental Biotechnology defines environmental biotechnology as "the development, use and regulation of biological systems for remediation of contaminated environments (land, air, water), and for environment-friendly processes (green manufacturing technologies and sustainable development)".[1]

Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".[2]

Science through the IAASTD has called for the advancement of small-scale agro-ecological farming systems and technology in order to achieve food security, climate change mitigation, climate change adaptation and the realisation of the Millennium Development Goals. Environmental biotechnology has been shown to play a significant roll in agroecology in the form of zero waste agriculture and most significantly through the operation of over 15 million biogas digesters worldwide.

Consider an environment in which pollution of a particular type is maximum. Let us consider the effluents of a starch industry which has mixed up with a local water body like a lake or pond. We find huge deposits of starch which are not so easily taken up for degradation by micro-organisms except for a few exemptions. we isolate a few micro-organisms from the polluted site and scan for any significant changes in their genome like mutations or evolutions. The modified genes are then identified. This is done because, the isolate would have adapted itself to degrade/utilize the starch better than other microbes of the same genus. Thus, the resultant genes are cloned onto industrially significant micro-organisms and are used for more economically significant processes like in pharmaceutical industry, fermentations...etc.

Similar situations can be elucitated like in the case of oil spills in the oceans which require cleanup, microbes isolated from oil rich environments like oil wells, oil transfer pipelines...etc. have been found having the potential to degrade oil or use it as an energy source. Thus they serve as a remedy to oil spills.

Still another elucidation would be in the case of microbes isolated from pesticide rich soils These would be capable of utilizing the pesticides as energy source and hence when mixed along with bio-fertilizers, would serve as excellent insurance against increased pesticide-toxicity levels in agricultural platform.

But the counter argument would be that whether these newly introduced microorganisms would create an imbalance in the environment concerned.The mutual harmony in which the organisms in that particular environment existed may have to face alteration and we should be extremely careful so as to not disturb the mutual relationships already existing in the environment of both the benefits and the disadvantages would pave way for an improvised version of environmental biotechnology. After all it is the environment that we strive to protect.

Humans have been manipulating genetic material for centuries. Although many benefits are provided by these manipulations, there can also be unexpected, negative health and environmental outcomes. Environmental biotechnology, then, is all about the balance between the applications that provide for these and the implications of manipulating genetic material.[3] Textbooks address both the applications and implications. Environmental engineering texts addressing sewage treatment and biological principles are often now considered to be environmental biotechnology texts. These generally address the applications of biotechnologies, whereas the implications of these technologies are less often addressed; usually in books concerned with potential impacts and even catastrophic events.

Go here to read the rest:
Environmental biotechnology - Wikipedia

From Wikipedia, the free encyclopedia

The Biotechnology Portal

Welcome to the Biotechnology portal. Biotechnology is a technology based on biology, especially when used in agriculture, food science, and medicine.

Of the many different definitions available, the one declared by the UN Convention on Biological Diversity is one of the broadest:

Refresh - Edit

Portal:Biotechnology/Selected questions/November

Biotechnology subcategories:

edit

Cloning is the process of creating an identical copy of an original. A clone in the biological sense, therefore, is a single cell (like bacteria, lymphocytes etc.) or multi-cellular organism that is genetically identical to another living organism. Sometimes this can refer to "natural" clones made either when an organism reproduces asexually or when two genetically identical individuals are produced by accident (as with identical twins), but in common parlance the clone is an identical copy by some conscious design. Also see clone (genetics). The term clone is derived from , the Greek word for "twig". In horticulture, the spelling clon was used until the twentieth century; the final e came into use to indicate the vowel is a "long o" instead of a "short o". Since the term entered the popular lexicon in a more general context, the spelling clone has been used exclusively.

edit

Portal:Biotechnology/Selected anecdote/November

edit

edit

edit

Purge server cache

Read more:
Portal:Biotechnology - Wikipedia

Food and feed generally originates from plants and animals grown and bred by humans for several thousand years. Over time, those plants and animals with the most desirable characteristics were chosen for breeding the next generations of food and feed. This was, for example, the case for plants with an increased resistance to environmental pressures such as diseases or with an increased yield.

These desirable characteristics appeared through naturally occurring variations in the genetic make-up of those plants and animals. In recent times, it has become possible to modify the genetic make-up of living cells and organisms using techniques of modern biotechnology called gene technology. The genetic material is modified artificially to give it a new property (e.g. a plant's resistance to a disease, insect or drought, a plant's tolerance to a herbicide, improving a food's quality or nutritional value, increased yield).

Such organisms are called "genetically modified organisms" (GMOs). Food and feed which contain or consist of such GMOs, or are produced from GMOs, are called "genetically modified (GM) food or feed".

Read this article:
Genetically Modified Organisms - European Commission

Program Goal:The biotechnology program is designed to prepare students for employment as technicians who will work in a laboratory or industrial setting. Biotechnology is a wide-ranging field encompassing: DNA/RNA and protein isolation, characterization, and sequencing; cell culture; genetic modification of organisms; toxicology; vaccine sterility testing; antibody isolation and production; and the development of diagnostic and therapeutic agents. This hands-on program is designed to meet local, statewide, and national need for laboratory technicians. Graduates are thoroughly grounded in basic laboratory skills and trained in advanced molecular biology techniques. Students are acclimated to both research and industrial environments. The program emphasizes laboratory-based, universal, and scalable technical skills resulting in a thorough and comprehensive understanding of the methodology.

Program Entrance Requirements: To be admitted into the biotechnology Degree Program, a student must have,

Achieved a level of English and reading proficiency which qualifies the student for entry into ENC 1101 or higher as demonstrated by the standard placement criteria currently in use at State College of Florida, Manatee-Sarasota (SCF)

Achieved a level ofmathematics proficiency which qualifies the student for entry into MAC 1105 or higher as demonstrated by the standard placement criteria currently in use at SCF

Achieved a level of chemistry and biological content proficiency equivalent to that covered in CHM 1025C and BSC 1007C as demonstrated by the standard placement criteria currently in use at SCF

Suggested course of study:

1

3

College Algebra

MAC 1105

3

4

Total Hours

12

4

3

Social and

Behavioral

Sciences

Must be an area III

Socialor Behavioral Science.

3

4

Total Hours

13

4

4

3

Total Hours

11

4

4

5

Total Hours

13

3

5

3

4

Total Hours

12

See more here:
Biotechnology A.S. Degree

Track 1:Pharmaceutical Biotechnology

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs.Pharmaceutical Biotechnologyis an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs,diagnosticagents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes inhealthcarepractices and a significant contribution to the development of national economy.Biopharmaceuticalsconsists of large biological molecules which areproteins. They target the underlying mechanisms and pathways of a disease or ailment; it is a relatively young industry. They can deal with targets in humans that are not accessible with traditional medicines.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; Global Biotechnology Congress 2016, May 11th - 14th 2016, Boston, MA, USA;BiomarkerSummit 2016, March 21-23, 2016 San Diego, CA, USA; 14th Vaccines Research & Development, July 7-8, 2016 Boston, USA; Pharmaceutical &Biotech Patent LitigationForum, Mar 14 - 15, 2016, Amsterdam, Netherlands;

Track 2:Biotechnology in Health Care

Biotechnology in health care represents the complex of modern biological approaches in the field of healthcare research and industry. Healthcare Biotechnology methods are used primarily in pharmaceutical industry and modern clinical diagnostics. The research training in this domain is programmed for the candidates intending to develop their careers in scientific-research institutions, clinical anddiagnostic laboratories, analytical services,pharmacologicalandpharmaceutical companies, etc. For the first time in the history of human healthcare, biotechnology is enabling the development and manufacturing of therapies for a number of rare diseases with a genetic origin. Although individually rare, collectively thesediseasesaffect some 20-30 million individuals and their families with 70-80% having a genetic component requiring biotechnology as part of the solution.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; 3rd CaribbeanBiomedicalResearch Days, January 16-18, 2016, Rodney Bay, Saint Lucia; GlobalBiotechnologyCongress 2016, May 11th-14th 2016, Boston, MA, USA;BiomarkerSummit 2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccinesResearch & Development, July 7-8, Boston, USA;Pharmaceutical&BiotechPatentLitigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkersinDiagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 3:Food Biotechnology

Food biotechnology is a process scientists use to enhance the production,nutritional value, safety, and taste of foods. It can also benefit the environment by improving crops so that they need fewerpesticides. The concept is not new: For centuries farmers have selectively bred plants to pass on desirable qualities. For example, our ancestors began by replanting only corn seeds from the highest yielding and best tasting corn they grew each year. This process selected desirable genes and fixed them by growing the seeds of the selected crop year after year. The result: the golden, deliciously sweet product we now enjoy. Modernfood biotechnologyis a refined version of this same process. Today, scientists obtain desired traits by adding or removing plant genes. This process is called genetic engineering or recombinant DNA technology. It yields foods that are flavorful, contain more vitamins and minerals, and absorb less fat when cooked, and gives us crops that are more resistant to pests and insects. Food biotechnology holds great promise for the future. Soon, fruits and vegetables may be made to resist drought. We may remove allergens from foods such as nuts. Scientists may develop plants that absorb nitrogen more efficiently and need lessfertilizer. The benefits are nearly limitless!

RelatedBiotechnology Conferences

3rdGlobal Food Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;BiologicallyActive Compounds inFood, October 15-16 2015 Lodz, Poland; World Conference on InnovativeAnimal NutritionandFeeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood ScienceandBiotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference onAgricultural Science,Biotechnology,FoodandAnimal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia; International Conference of Eco-friendlyApplied BiologicalControl ofAgricultural PestsandPhytopathogens, 19 -22 October 2015, Cairo, Egypt;Food Structures,DigestionandHealth3rd International Conference, 28-30 October, Wellington, New Zealand; Conference ofCereal BiotechnologyandBreeding, November 2-4, 2015, Berlin, Germany; AdvancedWater TreatmentforFood & Beverage, November 3-4, 2015 Amsterdam, Netherlands.

Track 4:Industrial and Microbial Biotechnology

Industrial or white biotechnology uses enzymes and micro-organisms to make biobased products in sectors such as chemicals,food and feed, detergents, paper and pulp, textiles andbioenergy. The application of industrial biotechnology has been proven to make significant contributions towards mitigating the impacts of climate change in these and other sectors. In addition to environmental benefits, biotechnology can improve industrys performance and product value and, as the technology develops and matures,white biotechnologywill yield more and more viable solutions for our environment. These innovative solutions bring added benefits for both our climate and our economy.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; GlobalBiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track 5:Nanobiotechnology

Nanobiotechnologyis beginning to allow scientists, engineers, and physicians to work at the cellular and molecular levels to produce major benefits to life sciences and healthcare. In the next century, the emerging field of nanotechnology will lead to new biotechnology based industries and novel approaches in medicine. Nanobiotechnology is that branch of nanotechnology that deals with biological and biochemical applications or uses. Nanobiotechnology often studies existing elements of living organisms and nature to fabricate newnano-devices. Generally, nanobiotechnology refers to the use of nanotechnology to further the goals of biotechnology. Some of the innovative challenges in the field of biology are: New molecular imaging techniques, Quantitative analytical tools, Physical model of the cell as a machine, Better ex-vivo tests and improvement in current laboratory techniques and Better drug delivery systems.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;NanoBioTech-Montreux, November 16-18, 2015, Switzerland; International Conference onNanobiotechnology(ICNB'16), April 1-2, 2016, Prague, Czech Republic; InternationalNanotechnologyConference & Expo, April 4-6, 2016 Baltimore, USA;

Track 6:Plant Biotechnology

Plant biotechnology is the technique used to manipulate the plants for specific needs or requirement. In traditional process seed is the major source for germinating a new plant but the advance method is independent that combines multiple needs to get the required traits.Plant biotechnologymeets the challenge that includesgenomics,genetic engineering,tissue culture, andtransgenic cropsetc. These biotechnological applications allow researchers to detect and map genes and discover their functions, selection of specific genes in genetic resources and its breeding and to customize the plant according to the requirement by transferring the genes of specific traits to combine with others to create a new species. The recent advances in plant biotechnology provide potential way to make improvements much more quickly than conventionalplant breedingtechniques. Plant tissue culture is a part of plant biotechnology which is the collection of many techniques that is used to maintain and grow plant, plant cells, plant tissues under controlled sterile conditions over the nutrient medium. Plant tissue culture is the convenient method produce clones of a plant through the process calledmicropropagation. The main advantage of this method is to produce exact and multiple copies of plants with good desired properties like good flowers, fruits and other characters within small span of time. Production of multiple plants without seed, production of genetically modified plants, the tissue culture plants are resistant to the diseases,pathogensand pests, also it is the best method to store the gene pools and many more

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; 3rd CaribbeanBiomedicalResearch Days, January 16-18, 2016, Rodney Bay, Saint Lucia;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA; 18th International Conference onAgricultural Biotechnology, Biological and Biosystems Engineering, January 18-19, 2016, London, United Kingdom; 2nd International Conference on Biotechnology andAgriculture EngineeringApril 08-09 2016 in Tokyo, Japan; Food Structures, Digestion andHealth3rd International Conference, 28-30 October 2015, Wellington, New Zealand; 3rd Conference ofCereal Biotechnologyand Breeding, November 2-4, 2015, Berlin, Germany;

Track 7:Agricultural Biotechnology

Agricultural biotechnologyis the area of biotechnology involving applications to agriculture. Agricultural biotechnology has been practiced for a long time, as people have sought to improve agriculturally important organisms by selection and breeding. An example of traditional agricultural biotechnology is the development of disease-resistant wheat varieties by cross-breeding different wheat types until the desired disease resistance was present in a resulting new variety. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques as Marker Assisted Breeding, which increases the effectiveness of conventional breeding. Whatever the particular technology used, the crops may be destined for use for food,biomaterialsor energy production.Genetic modificationmeans that existing genes are modified or new genes included to give plant varieties desirable characteristics, such as resistance to certain pests or herbicides, or forvitaminfortification. Because only a few genes with known traits are transferred, GM methods are more targeted and faster thantraditional breeding. Biotechnology has helped to increase crop productivity by introducing such qualities as disease resistance and increased drought tolerance to the crops.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrialBiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; Conference onAgricultural Statistics2015, Sarawak, Malaysia; 2nd International Conference onGlobal Food Security, 11-14 October 2015, Ithaca, United States; 5th International Conference onOrganic AgricultureSciences, 14th-17th October 2015, Bratislava, Slovakia; 18thInternational Conference onAgricultural, Biotechnology, Biological and Biosystems Engineering, January 18-19, 2016, London, United Kingdom; 2nd International Conference on Biotechnology andAgriculture EngineeringApril 08-09 2016 in Tokyo, Japan;Food Structures, Digestion andHealth3rd International Conference, 28-30 October 2015, Wellington, New Zealand; 3rd Conference of Cereal Biotechnology andBreeding, November 2-4, 2015, Berlin, Germany; AdvancedWater TreatmentforFood & Beverage, 3-4 Nov 2015, Amsterdam, Netherlands

Track 8:Environmental Biotechnology

Environmental biotechnology is biotechnology that is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. The International Society for Environmental Biotechnology defines environmental biotechnology as "the development, use and regulation of biological systems for remediation of contaminated environments (land, air, water), and for environment-friendly processes (green manufacturing technologies and sustainable development)

RelatedBiotechnology Conferences

5th International Conference onBiodiversity, March 10-12, 2016 at Madrid, Spain; International Conference on Biotechnology andEnvironmental ManagementSeptember 14-15 Milan, Italy; 6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; International Conference onGreen Energy& Expo September 21-23, 2015 Orlando, FL, USA; International Conference on Environment,Energy and Biotechnology, May 25, 2016 Jeju Island, Republic of Korea; International Conference on Energy andEnvironmental Biotechnology, November 24 - 25, 2015 Dubai, UAE; Science for theEnvironmentConference 2015, October 1-2 2016 Aarhus, Denmark; International Conference onEnvironmental Scienceand Technology 14th to 17th May 2016, Antalya, Turkey

Track 9:Marine Biotechnology

Marine Biotechnology is a relatively new field of study, having emerged in the past few years. The Marine Biotechnology is intended to host scientific contributions inmarine sciencethat are based on the enormousbiodiversityof marine ecosystems and the genetic uniqueness of marine organisms to develop useful products and applications.Aquaculture& Marine Biotechnology have been the subject of great importance not only because of the sustainable utilization of their resources to feed the billion people of the world but also for the future challenges for discovery of new products and process development of economic importance through its treasure recognition and diversification. Apart from contributing to high quality and healthy food (aquaculture),nutraceuticalsand medicinal products (anti-cancer andantimicrobials), this sector is expected to contribute to sustainable alternative source of energy (biofuelfrom microalgae) and environmental health. Marine Biotechnology is capable of making an important contribution towards meeting impending challenges like a sustainable supply of food and energy and human health.

RelatedBiotechnology Conferences

5th International Conference on Biodiversity, March 10-12, 2016 at Madrid, Spain; International Conference on Biotechnology and Environmental Management September 14-15, Milan, Italy; 6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;BioMarine2015, 12-14 Oct 2016, Wilmington, NC, United States; International Conference onMarine BiotechnologyandBioprocessing, December 10 - 11, 2015, Sydney, Australia; Annual world congress ofMarine Biotechnology-2015, November 6-8 2015, Qingdao, China;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA; Annual InternationalMarine BiotechnologyConference, Nov 20, 2013, Brisbane, Australia

Track 10:Current Scenario of Biotechnology

Due to multidisciplinary nature of the field of biotechnology, a wide range of different branches of science have made significant contributions to the fast development of this field. Some of these disciplines are-biochemical engineering,physiology,biochemistry,food science,material science,bioinformatics,immunology,molecular biology,chemical engineeringetc. Biotechnology is also improving the lives of people around the world. Biotechnology also has affected economy in a positive way due to the creation and growth of small business, generation of new jobs. Agricultural biotechnology has reduced our dependency on pesticides.Bioremediation technologiesare being used to clean our environment by removing toxic substances from contaminated ground water and soils. about 60% of the biotechnology products in the market are healthcare products and 21% are products used in agriculture andanimal husbandry. A considerable amount of efforts in research are on, to use and extract benefit from this interesting and upcoming field for the betterment of human life and the environment. Many biochemical companies are involved in the production of biotechnological products usinggenetic engineeringtechniques.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;

Track 11:Animal Biotechnology

Biotechnology provides new tools for improvinghuman healthand animal health and welfare and increasinglivestock productivity. Biotechnology improves the food we eat-meat, milk and eggs. Biotechnology can improve an animals impact on the environment. And biotechnology enhances ability to detect, treat and prevent diseases. Just like other assistedreproduction techniquessuch asartificial insemination,embryo transferandin vitro fertilization, livestockcloningimproves animal breeding programs allowing farmers and ranchers to produce healthier offspring, and therefore producer healthier, safer and higher quality foods more consistently.

RelatedBiotechnology Conferences|Biotechnology Events|Biochemistry Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;BiomarkerSummit 2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccinesResearch & Development, July 7-8, Boston, USA;

Track 12:Biomass and Bioenergy

Bioenergyis the chemical energy contained in organic matter (biomass) which can be converted into energy forms that we can use directly, such as electricity, heat and liquid fuel. Biomass is any organic matter of recently living plant or animal origin. Unlike coal, the organic matter is notfossilised.Bioenergy plantscan range from small domestic heating systems to multi-megawatt industrial plants requiring hundreds of thousands of tonnes ofbiomassfuel each year. A variety of technologies exists to release and use the energy contained in biomass. They range from combustion technologies that are well proven and widely used around the world for generating electricity generation, to emerging technologies that convert biomass intoliquid fuelsfor road, sea and air transport.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA; IEABioenergyConference 2016, October 26th-29th2016, Berlin, Germany; Summit onIndustrial biotechnologyandBioenergy, December 7 -9, 2016 San Diego, California; Energy Conference, Des Moines, Oct 13-15 Iowa, USA; EuropeanBiomassConference and Exhibition Amsterdam, 6-9, June, Germany Netherlands; EcoSummit 2016, August 29 - September 01 2016, Montpellier, France; InternationalBioenergyand Bioproducts Conference, October 28-30, 2016 Atlanta, Georgia; 2016 InternationalBiomassConference & Expo, Charlotte, North Carolina;World Bioenergy2016, May 24-26 2016, Stockholm, Sweden; 2016 InternationalFuel EthanolWorkshop & Expo, June 20-23, 2016 Milwaukee, Wisconsin.

Track 13:Biotechnology and its Applications

The applications of biotechnology are so broad, and the advantages so compelling, that virtually every industry is using this technology. Developments are underway in areas as diverse aspharmaceuticals, diagnostics,textiles,aquaculture,forestry, chemicals, household products,environmental cleanup,food processingand forensics to name a few. Biotechnology is enabling these industries to make new or better products, often with greater speed, efficiency and flexibility. Biotechnology holds significant promise to the future but certain amount of risk is associated with any area.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA; IEABioenergyConference 2016, October 26th-29th2016, Berlin, Germany; Summit onIndustrial biotechnologyandBioenergy, December 7 -9, 2016 San Diego, California;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;

Track 14:Biotechnology Market

The growth of Biotechnology industry as per Transparency Market Research is estimated to observe substantial growth during 2010 and 2017 as investments from around the world are anticipated to rise, especially from emerging economical regions of the world. The report states that the global market for biotechnology, studied according to its application areas, shall grow at an average annual growth rate of CAGR 11.6% from 2012 to 2017 and reach a value worth USD 414.5 billion by the end of 2017. This market was valued approximately USD 216.5 billion in 2011. The market of bioagriculture, combined with that of bioseeds, is projected to reach a value worthUSD 27.46 billionby 2018. The field of biopharmaceuticals dominated the global biotechnology market and accounted for 60% shares of it in the year 2011. Many biotechnological industries flourished by the technological advancements leading to new discoveries and rising demands from the pharmaceutical and agricultural sectors.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA; BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil; BioPharm Americ 2015-8thAnnual International Partnering Conference, September 15-17, 2015, Boston, MA, USA;

Track 15: Biotech Companies and Market Analysis

The biotechnology community in Europe has seen significant growth in recent years. By establishing itself in several key niche markets, the European biotech and pharma industries have thrived in the global biopharmaceutical market. Europe high standards for their life science educational systems have increased the level of growth and the quality of Europes workforce and broadened Europes reach within the world. With a dedication to innovation and research, Europe has established itself as a leader in biotechnology.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA; BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil; BioPharm Americ 2015-8thAnnual International Partnering Conference, September 15-17, 2015, Boston, MA, USA;

Track 16: Biotech Startups and Funding:

Biotechnology being an emerging industry, game-changing strategies and relevant application of the knowledge-intelligence resource pool, drive the process of growth. Europe Biotechnology seeks to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the industry by offering a vibrant global platform for convergence of the key stakeholders - Biotech & Biopharma Companies, research institutions, investors, service providers, policy makers, regulators and analysts.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA; BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil; BioPharm Americ 2015-8thAnnual International Partnering Conference, September 15-17, 2015, Boston, MA, USA;

Track 17: Advances in Biotech Manufacturing

The biotechnology community in Asia has seen significant growth in recent years. By establishing itself in several key niche markets, the European biotech and pharma industries have thrived in the global biopharmaceutical market. Asias high standards for their life science educational systems have increased the level of growth and the quality of Asias workforce and broadened Asias reach within the world. With a dedication to innovation and research, Asia has established itself as a leader in biotechnology.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA; BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil; BioPharm Americ 2015-8thAnnual International Partnering Conference, September 15-17, 2015, Boston, MA, USA;

Track 18: Biotech Investors and Grants

The biotechnology industry hauled in $2.3 billion worth of venture capital investments during the second quarter of this yeara 32% increase over the prior quarter, according to the newest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters. The 126 deals struck during the period marked the biggest quarterly investment in biotech since the MoneyTree report first came out in 1995, and it brought the total for the first half to $3.8 billion.

RelatedBiotechnology Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 2ndIndustrial BiotechnologyCongress, July 28-29, 2016, Berlin, Germany; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA;Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA; BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil; BioPharm Americ 2015-8thAnnual International Partnering Conference, September 15-17, 2015, Boston, MA, USA;

8th Euro Biotechnology Congress (Euro Biotechnology-2015) was held during August 18-20, 2015 at Flemings Conference Hotel, Frankfurt, Germany. The conference was marked with the attendance of Editorial Board Members of supported OMICS Group Journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 30 countries, who made this conference fruitful and productive.

This conference was based on the theme Biotechnology for a Better Tomorrow which included the following scientific tracks:

Biotechnology in Health Care Environmental Biotechnology Industrial Aspects of Biotechnology Stem Cells and Regenerative Medicine Marine Biotechnology and Aquaculture Agriculture Biotechnology Animal Biotechnology Food and Bio Process Biotechnology Cell and Molecular Biology Nanobiotechnology Genetic Engineering and rDNA Technology Current Scenarios and other allied areas of Biotechnology

We are thankful to our below Honourable guests and Keynote Speakers for their generous support and suggestions.

Manfred T Reetz Philipps-University, Germany

W Tim Miller - Echelon-Frontier Scientific Inc, USA

Wilfried Schwab - Technische Universitt Mnchen, Germany

Aline Zimmer- Merck Millipore, Germany

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following topics were highlighted as Keynote-presentations:

Increasing the efficiency of directed evolution of enzymes: Manfred T Reetz, Philipps-University of Marburg, Germany

Trade secrets and laboratory security: Frontier Scientific Inc, USA

Aroma glucoside production: Wilfried Schwab, Technische Universitt Mnchen, Germany

Chemically modified cysteine in fed-batch processes and impact on CHO specific productivity: Aline Zimmer, Merck Millipore, USA

Synthetic mRNAs present a rapidly growing technology: Optimized tool for stem cell generation and for manipulating cellular phenotypes : Guido Krupp, Amptec GmbH, Germany

Novel synthetic anti-microbial defensins through confrontational selection and screening of yeast libraries: K Yankulov, University of Guelph, Canada

Long acting recombinant glycoprotein hormones: From bench to clinics, Fuad Fares, University of Haifa, Israel

Poster Session was judged by K Yankulov, University of Guelph, Canada

The esteemed guests, Keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Euro Biotechnology-2015. We are glad to inform that all accepted abstracts for the conference have been published in OMICS Group Journal of Biotechnology & Biomaterials as a special issue.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. With the unique feedback from the conference, OMICS Group would like to announce the commencement of the 11th Euro Biotechnology Congress" to be held during November 07-09, 2016 at Alicante, Spain

Let us meet Again @ Euro Biotechnology-2016

Biotechnology-2014

OMICS Group Conferencessuccessfully hosted its premier5thWorld Congress on Biotechnologyduring June25-27, 2014 Valencia Conference centre, Valencia Spain

This World congress was accomplished by the support of European Biotechnology Thematic Network Association (EBTNA), Valencia Bioregion (BIOVAL), Federation of Spanish Biotechnologist (FEBiotec) and Societ Italo-Latinoamericana di Etnomedicina (SILAE). Biotechnology-2014 marked with the attendance of Editorial Board Members of supported OMICS Group Journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who made this conference fruitful and productive.

This5thWorld Congress on Biotechnologywas based on the theme the theme Biotechnology: Meeting the Needs of a Changing World which has covered the below scientific sessions:

The conference was greeted by the welcome message ofProf. Cheorl-Ho KimSung Kyun Kwan University, Korea and moderated byProf. Martin J. DSouza, Mercer University, USA. The support was extended by the below honourable guest Em. Prof.Marc Van Montagu, (World Food Laureate 2013) University of Gent, Belgium, Prof.Roberto Gaxiola, Arizona State University, USA, Prof.Ara Kanekanian, Cardiff Metropolitan University, UK, Prof.Manuel P. Alonso,University of Valencia, Spain, Prof.Cheorl-H. Kim,Sung Kyun Kwan University,Dr. Srinubabu Gedela, OMICS Group Inc, USA and below keynote lectures:

OMICS GroupInternational acknowledge the support of below Chairs and Co-chairs foe whom we were able to run smoothly the scientific sessions includes: Alain Goossens, Ghent University, Belgium, Oscar Vicente, IBMCP, Polytechnic University of Valencia, Spain, Ara Kanekanian, Cardiff Metropolitan University, UK, Ana M. Hortigela, Instituto de Medicina Genmica, Spain, Cheorl-H Kim, Sung Kyun Kwan University, Korea, Martin J. DSouza, Mercer University, USA, Marina V. Frontasyeva, Joint Institute for Nuclear Research, Russian Federation, Zlatka Alexieva, Bulgarian Academy of Sciences, Bulgaria, Salvador Ventura, Universitat Autnoma de Barcelona, Spain, Giuseppe Manco, Institute of Protein Biochemistry, National Research Council (CNR), Italy, Aihua Liu, Qingdao Institute of Bioenergy & Bioprocess, CAS, China, Amparo Pascual-Ahuir Giner, Universidad Politecnica de Valencia, Spain.

Go here to see the original:
Biotechnology Conferences | Biotechnology Events - Europe

UMBC Biotechnology Graduate Programs

The Masters in Professional Studies in Biotechnology prepares science professionals to fill management and leadership roles in biotechnology-related companies or agencies.

UMBCs Biotechnology curriculum is intended to address changes in the needs of the biotechology industry through experiential learning, by providing advanced instruction in the life sciences, in addition to coursework in regulatory affairs, leadership, management, and financial management in a life science-oriented business.

Global challenges in human health, food security, sustainable industrial production and environmental protection continues to fuel the biosciences industry, creating new opportunities within the four primary sub sectors:

UMBC's Biotechnology Graduate Program and its strong academic programs in the life sciences are led by a distinguished faculty of nearly fifty members spanning the departments of:

This established academic and research expertise in the biosciences provides a foundation for programs in biotechnology management and biochemical regulatory engineering.

Over the past decade the industry has added nearly 111,000 new, high-paying jobs or 7.4 percent to its employment base, according to the latest Battelle/BIO report.

Economic output of the bioscience industry has expanded significantly with 17 percent growth for the biosciences since 2007, nearly twice the national private sector nominal output growth.

UMBC Division of Professional Studies 1000 Hilltop Circle, Sherman Hall East 4th Floor, Baltimore, MD 21250 410-455-2336 dps@umbc.edu

Link:
Biotechnology at UMBC

Broadly speaking, biotechnology is any technique that uses living organisms or substances from these organisms to make or modify a product for a practical purpose (Box 2). Biotechnology can be applied to all classes of organism - from viruses and bacteria to plants and animals - and it is becoming a major feature of modern medicine, agriculture and industry. Modern agricultural biotechnology includes a range of tools that scientists employ to understand and manipulate the genetic make-up of organisms for use in the production or processing of agricultural products.

Some applications of biotechnology, such as fermentation and brewing, have been used for millennia. Other applications are newer but also well established. For example, micro-organisms have been used for decades as living factories for the production of life-saving antibiotics including penicillin, from the fungus Penicillium, and streptomycin from the bacterium Streptomyces. Modern detergents rely on enzymes produced via biotechnology, hard cheese production largely relies on rennet produced by biotech yeast and human insulin for diabetics is now produced using biotechnology.

Biotechnology is being used to address problems in all areas of agricultural production and processing. This includes plant breeding to raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Biotechnology is being used to develop low-cost disease-free planting materials for crops such as cassava, banana and potato and is creating new tools for the diagnosis and treatment of plant and animal diseases and for the measurement and conservation of genetic resources. Biotechnology is being used to speed up breeding programmes for plants, livestock and fish and to extend the range of traits that can be addressed. Animal feeds and feeding practices are being changed by biotechnology to improve animal nutrition and to reduce environmental waste. Biotechnology is used in disease diagnostics and for the production of vaccines against animal diseases.

Clearly, biotechnology is more than genetic engineering. Indeed, some of the least controversial aspects of agricultural biotechnology are potentially the most powerful and the most beneficial for the poor. Genomics, for example, is revolutionizing our understanding of the ways genes, cells, organisms and ecosystems function and is opening new horizons for marker-assisted breeding and genetic resource management. At the same time, genetic engineering is a very powerful tool whose role should be carefully evaluated. It is important to understand how biotechnology - particularly genetic engineering - complements and extends other approaches if sensible decisions are to be made about its use.

This chapter provides a brief description of current and emerging uses of biotechnology in crops, livestock, fisheries and forestry with a view to understanding the technologies themselves and the ways they complement and extend other approaches. It should be emphasized that the tools of biotechnology are just that: tools, not ends in themselves. As with any tool, they must be assessed within the context in which they are being used.

Read the rest here:
1. What is agricultural biotechnology? - GreenFacts